Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epiderman growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial

Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epiderman growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial

Bibliographic Details
Main Authors: Eiermann, W., Pienkowski, T., Crown, J., Sadeghi, S., Chan, Arlene, Saleh, M., Sehdev, S., Provencher, L., Semiglazov, V., Press, M., Sauter, G., Lindsay, M., Riva, A., Buyse, M., Drevot, P., Taupin, H., Mackey, J.
Format: Journal Article
Published: American Society of Clinical Oncology 2011
Online Access:http://hdl.handle.net/20.500.11937/10830

Internet

http://hdl.handle.net/20.500.11937/10830

Similar Items